Clinical Trial Update: Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial examining lenzilumab in combination with axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma was terminated; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• Axicabtagene ciloleucel (axicabtagene ciloleucel)
• Lenzilumab (lenzilumab)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed/Refractory Large B-cell Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2024-03-04